TBC 609
Alternative Names: TBC609Latest Information Update: 05 Feb 2008
At a glance
- Originator Encysive Pharmaceuticals
- Class Antirheumatics; Peptides; Vascular disorder therapies
- Mechanism of Action Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Ischaemic heart disorders; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 20 Jul 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
- 20 Jul 1998 No-Development-Reported for Multiple sclerosis in USA (Unknown route)